HIMARS: Stereotactic radiation for prostate cancer spread
Part of Cancer clinical trials.
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to bones or lymph nodes and has worsened after at least one standard treatment like hormone therapy or chemo.
- You are able to get around and take care of yourself (ECOG score under 3).
- Your cancer spread is in bones or lymph nodes that can safely be treated with targeted radiation.
- Your blood counts are adequate: low white cells above 1,000, platelets above 50,000, or hemoglobin above 8 g/dL.
- You are at least 18 years old and willing to follow the study schedule.
- Your life expectancy is more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to the prostate and cancer spread sites helps men whose prostate cancer has spread to bones but isn't responding well to standard hormone treatments. You'd be eligible if your PSA level (a cancer marker) stays high after six months of dual hormone therapy.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.